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Background: Early and accurate diagnosis of Plasmodium falciparum infection is important for providing
appropriate treatment to patients with malaria. However, technical limitations of currently available diagnostic
tests limit their use in control programs. One possible explanation for the vulnerability of current antibodies
used in RDTs is their propensity to degrade at high ambient temperatures. Isolation of new antibodies with
better thermal stability represents an appealing approach to improve the performance of RDTs.
Methods: In this study, phage display technology was deployed to isolate novel binders by screening a human
naïve scFv antibody library against recombinant Plasmodium falciparum histidine rich protein 2 (rPfHRP2). The
isolated scFv clones were reformatted to whole IgG and the recombinant mAbs were produced in a mammalian
CHO cell expression system. To verify the biological activity of these purified recombinant mAbs, range of
functional assays were characterized.
Results: Two unique clones (D2 and F9) were isolated after five rounds of biopanning. The reformatted and
expressed antibodies demonstrated high binding specificity to malaria recombinant PfHRP2 and native proteins.
When 5 μg/mL of mAbs applied, mAb C1-13 had the highest sensitivity, with an OD value of 1, the detection
achieved 5 ng/mL of rPfHRP2, followed by mAbs D2 and F9 at 10 ng/mL and 100 ng/mL of rPfHRP2, respectively.
Although the sensitivity of mAbs D2 and F9 was lower than the control, these recombinant human mAbs have
shown better stability compared to mouse mAb C1-13 at various temperatures in DSC and blot assays. In view of
epitope mapping, the predominant motif of rPfHRP2 recognized by mAb D2 was AHHAADAHHA, whereas mAb
F9 was one amino acid shorter, resulting in AHHAADAHH. mAb F9 had the strongest binding affinity to rPfHRP2
protein, with a KD value of 4.27 × 10
−11 M, followed by control mAb C1-13 at 1.03 × 10−10 M and mAb D2 at
3.05 × 10−10 M.
Conclusions: Overall, the performance of these mAbs showed comparability to currently available PfHRP2-specific
mouse mAb C1-13. The stability of these novel binders indicate that they merit further work to evaluate their utility
in the development of new generation point of care diagnosis of malaria.* Correspondence: herng.leow@usm.my
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Malaria, caused by five species of human Plasmodium
and, of these species, infection with Plasmodium falcip-
arum is the most prevalent and lethal, causing significant
morbidity and mortality worldwide [1]. Therefore, it is
crucial to understand the important parameters in the
transmission of the disease, and develop effective diagnos-
tic strategies for its prevention and control.
Today, rapid diagnostic tests (RDTs) are increasingly
used for malaria diagnosis by detection of parasite bio-
markers as they offer a result within 20 minutes. In these
tests, Plasmodium lactate dehydrogenase (pLDH), and
fructose 1,6-biphosphate aldolase (Aldolase) are com-
monly used as candidate targets for detection of infection
with other Plasmodium species [2-4]. However, P. falcip-
arum histidine-rich protein 2 (PfHRP2) is a biomarker
that is predominantly used as a target for detection of
P. falciparum infection [5,6]. PfHRP2 is a water-soluble
protein that is produced by the asexual stages and game-
tocytes of P. falciparum. This protein is abundantly
expressed in the red cell, released during rupture of
infected red cells and can remain in the blood for up to
28 days after the initiation of anti-malarial therapy,
making it an excellent biomarker for diagnosis [7-9].
A number of technical issues which limit the utility of
malaria RDTs have been documented. An important one
is their limited shelf life, due to the temperature sensitive
capture and detecting antibody reagents [10,11]. As RDTs
are increasingly being deployed in remote tropical areas,
this problem could potentially lead to inaccurate diagnosis
and misuse of drugs [12]. Therefore, newly and more
stable antigen binders represent important objectives in
improving malaria RDT performance.
The aim of this study was to isolate new monoclonal
antibodies (mAbs) to PfHRP2 that may have better specifi-
city and stability than those currently used in RDTs. To
this end, a human single chain variable fragment (scFv)
naïve library was screened to isolate unique binders spe-
cific for PfHRP2 using phage display technology. Antibody
phage display has been extensively used for isolation of
high affinity specific binders against unique antigens from
different targets [13-17]. This technology was first intro-
duced by Smith in 1985 and has been widely used in diag-
nostic and therapeutic applications as previously reviewed
[18,19]. Such recombinant antibodies have been shown to
be effective in targeting different biomarkers in various
diseases. Over the past ten years, about 30% of human
therapeutic antibodies that have reached clinical trials
have been identified by phage display technology [20,21].
Methods
Malaria PfHRP2 antigen
A recombinant PfHRP2 malaria protein encoded by the
DNA sequence of the P. falciparum line FCQ79 [22],fused with thioredoxin tag and expressed in Escherichia
coli by DNA recombinant technology (Nelson Lee, unpub-
lished) was used. This recombinant protein, rPfHRP2, has
been shown to react with a set of PfHRP2-specific mouse
monoclonal antibodies [23].
Isolation of PfHRP2-specific scFv antibodies by phage
display
The ‘Sheets’ naive human scFv phage display library,
with a reported diversity of 6.7 × 109 members isolated
from peripheral blood lymphocyte cDNA from five dif-
ferent donors, was kindly provided by Prof James Marks
(University of California, San Francisco, USA) [24].
Iterative rounds of biopanning were performed to iso-
late human scFv specific for rPfHRP2 from the amplified
Sheets library. Briefly, two lots of 100 μg/mL purified
thioredoxin (Sigma-Aldrich, USA) in phosphate buffered
saline (PBS), and one lot of 100 μg/mL rPfHRP2 protein
in PBS were incubated overnight at room temperature in
immunotubes (Nunc Maxisorp; Denmark). The next
day, the immunotubes were rinsed and blocked with
2% skimmed milk powder (Diploma, Australia) in PBS
(MPBS) for 1 hour at room temperature. Phage particles
(1.2 × 1013) were blocked in 2% MPBS for 1 hour at room
temperature and then incubated for two sequential 1-hour
incubations in the thioredoxin-coated immunotubes. The
unbound phage were then transferred to the rPfHRP2-
coated tube and incubated for a further 1 hour at room
temperature. Unbound phage were removed by washing
five times with 0.1% Tween 20 in PBS (PBST). Bound
phage were eluted with 1 mL of 200 mM glycine at
pH 2.5, and the eluate was immediately neutralized by
adding 0.5 mL of 1 M Tris–HCl, pH 7.4. Eluted phage
were infected into log phase XL1-Blue E. coli bacteria, and
then amplified by growth in 50 mL of 2YT medium sup-
plemented with 100 μg/mL ampicillin and 2% glucose.
Phage were rescued by infection with 1 × 1011 pfu of
M13K07 helper phage (NEB, USA), followed by overnight
incubation at 30°C in 2YT medium supplemented with
100 μg/mL ampicillin and 30 μg/mL kanamycin. Rescued
phage were concentrated from the culture supernatant by
precipitation with 4% PEG 6000 and 0.5 M NaCl, then
used for the next round of panning. In total, five rounds
of selections were performed with antigen concentrations
of 100 μg/mL for rounds 1 and 2, 50 μg/mL for round 3,
25 μg/mL for round 4 and, 12.5 μg/mL for round 5.
Analysis of isolated clones
Following panning, the phage pool and isolated clones
were evaluated for binding against recombinant PfHRP2
by polyclonal and monoclonal ELISA, respectively. Briefly,
the binding reactivity of phage supernatant was tested in
96-well ELISA plates (Nunc Maxisorp, Denmark) coated
with 10 μg/mL of rPfHRP2 and blocked with 2% MPBS.
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conjugated anti-M13 monoclonal antibody (GE Health-
care, Australia). The DNA sequence of positive clones was
determined by Sanger sequencing in Applied Biosystems
Sequencer Model 3100 using pHEN1 sequencing primers.
After sequencing, the amino acid sequences were deduced
and aligned using ClustalW; the three complementar-
ity determining regions (CDRs) and four framework
(FW) regions in each of variable heavy (VH) and vari-
able light (VL) chain regions were identified using the
IMGT V-Quest software and VBASE2 immunoglobulin
database [25].
Antibody reformatting
To reformat the scFv fragments to whole, fully human
IgG, the variable regions for both the heavy and kappa
light chains of the rPfHRP2 specific scFv clones D2 and
F9 were PCR amplified from the phagemid vectors and
cloned into SacI-linearized ReformAb vectors (Acyte
Biotech, Australia) as previously described [26].
Mammalian cell expression and purification
The expression and purification of mAbs D2 and F9 was
undertaken as previously described [26]. Briefly, the
heavy and light chain plasmids were co-transfected into
suspension-adapted Chinese hamster ovary (CHO) cells
after mixing of plasmids with polyethylenimine (PEI).
After four hours, cells were diluted by doubling the total
volume with CD-CHO media, and insulin-like growth
factor 1 (IGF-1) (Novozymes, USA) was added at a con-
centration of 0.1 mg/L. The cultures were then transferred
to a humidified incubator and maintained at 32°C and
7.5% CO2 for seven to 14 days with shaking (250 rpm).
Antibodies were purified using Protein A affinity chroma-
tography. Bound antibodies were eluted at low pH and
then immediately buffer exchanged into PBS. Protein con-
centration was determined by absorbance at 280 nm, and
used to determine the yield. The quality of purified
monoclonal antibodies (D2 and F9) was determined
by SDS-PAGE gel and size-exclusion high-performance
liquid chromatography (HPLC) analysis.
Antibody binding sensitivity determined by endpoint
dilution ELISA
To understand the binding efficacy of these mAbs, a mal-
aria PfHRP2-specific mAb C1-13 (kindly provided by Dr
Martin Bubb, National Products Institute, South Africa)
was used as positive control in this study. mAb C1-13 is a
commercial mouse IgG1 mAb with binding specificity
against PfHRP2, that has been reported in previous
studies [23,27].
Microtitre plates (Greiner Bio-One, Germany) were
coated with 100 μL of diluted rPfHRP2 protein (1 μg/mL)
and blocked with 2% MPBS. After three wash steps with0.1% PBST, the blocked wells were incubated with 100 μL
of two-fold serial diluted mAbs D2 and F9, and control
antibody C1-13, starting at 20 ng/mL for 1 hour at room
temperature. Plates were washed with 0.1% PBST. One-
hundred μL of secondary detection antibody was added,
using goat anti-human antibody-conjugated HRP (Cat #:
A8667) (Sigma-Aldrich; MO, USA), diluted 1:5,000 in 2%
MPBS for D2 and F9 wells, or secondary goat anti-mouse
antibody-conjugated HRP (Cat #: 115-035-003) (Jackson,
USA), diluted 1:5,000 in 2% MPBS for C1-13 wells. Plates
were incubated at room temperature for 1 hour. After
washing with 0.1% PBST, 100 μL of freshly prepared OPD
solution (Sigma, USA) was added to each well, and ab-
sorbance read at a wavelength of 405 nm using ELISA
plate reader (Biotek Synergy HT, USA).
Antibody binding specificity to rPfHRP2 and native
proteins by Western blot
Saponin lysis was used to lyse the erythrocyte cell mem-
branes, a process that leaves the cell membrane intact. P.
falciparum culture was undertaken with the reference
strain 3D7 in human O + blood (Red Cross Blood Service,
Brisbane). Cultures were synchronized and harvested
at 5–10% parasitaemia. The parasite sample was then
washed and purified as described previously [28], and
mixed 1:1 with 2× reducing SDS-PAGE sample buffer.
Following SDS-PAGE electrophoresis, the separated
rPfHRP2 proteins (1 μg/mL), and native protein (1 μg/mL)
were transferred to nitrocellulose membrane (Hybond-c
Amersham Bioscience, UK). Uninfected red cells from the
same lot were used as controls. Membranes were blocked
in 5% MPBS and incubated for 1 hour at room tempe-
rature. After three wash steps with 0.1% PBST, 30 mL of
test mAbs at a concentration of 10 μg/mL was incubated
on the membrane at room temperature for 1 hour with
gentle shaking. Following three wash steps with 0.1% PBST,
membranes were incubated with secondary goat anti-
human antibody-conjugated HRP (Cat#: A8667) (Sigma-
Aldrich, USA) that was diluted 1:10,000 in 5% MPBS for
mAbs D2 and F9 or goat anti-mouse antibody-conjugated
HRP (Cat#: 115-035-003) (Jackson, USA) that was diluted
1:10,000 in 5% MPBS for mAb C1-13. The detection
of HRP-conjugated secondary antibody was performed
using ECL chemiluminescence detection kit (Amersham
Bioscience, USA).
Antigen sensitivity determined by ELISA
Microtitre plates (Nunc Maxisorp, USA) were coated with
ten-fold serially diluted rPfHRP2 protein (100 μL/well),
with a starting concentration of 1 μg/mL. Plates were then
blocked in 2% MPBS and washed three times with 0.1%
PBST. The primary test antibodies (D2, F9 and C1-13)
were prepared at concentrations of 1 μg/mL and 5 μg/mL
and 100 μL were added to corresponding wells and the
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scribed above.Sensitivity determined by dot blot
10–15 μL of 1,000-fold serially diluted rPfHRP2 protein
(starting at 1 μg/mL) was transferred to the nitrocellulose
membrane (Hybond-C, Amersham Bioscience, UK) by
vacuum aspiration. After blocking in 5% MPBS for 1 hour,
the membranes were cut into small strips and placed into
corresponding tubes which contained 30 mL of appropri-
ate test antibodies (D2, F9 and C1-13) at concentrations
of 1 μg/mL and 5 μg/mL. The blot images were developed
as described above.Sandwich configuration studies
Microtitre plates coated with 100 μL of capture antibodies
D2, F9 or C1-13 (10 μg/mL) were blocked by 300 μL of 5%
MPBS. Ten-fold serially diluted rPfHRP2 protein dilutions
(starting at 1 μg/mL) were transferred to the corresponding
wells and incubated for 1 hour. After three washes with
PBST, bound antigen was detected by incubation with
100 μL of mAbs D2 or F9 (10 μg/mL) (for plates coated
with C1-13), or C1-13 (10 μg/mL) (for plates coated with
D2 and F9). After incubation at room temperature for
1 hour, plates were washed as described above. Detection
was achieved using 100 μL of mouse anti-human antibody-
conjugated HRP (Sigma-Aldrich, MO, USA) for wells with
mAbs D2 and F9 detection antibodies or goat anti-mouse
antibody conjugated HRP for wells using C1-13 detecting
antibody in 2% MPBS as described above.Heat lability determined by differential scanning calorimetry
The melting point of purified mAbs D2, F9 and C1-13 was
measured by differential scanning calorimetry (DSC) using
a NanoDSC Microcalorimeter (TA Instrument, USA) at an
antibody concentration of 1.0 mg/mL. The antibodies were
scanned at a rate of 1°C per minute from 25°C to 110°C,
and analysed using DSC software.Binding efficacy of mAbs stored at different temperatures
by dot blot analysis
Ten to 15 μL of two-fold serially diluted rPfHRP2 pro-
tein (starting at 1 μg/mL) was transferred to nitrocellu-
lose membrane by vacuum aspiration. After blocking in
5% MPBS at room temperature for 1 hour, membranes
were cut into small strips and placed into corresponding
tubes which contained 30 mL of test D2, F9 and control
C1-13 antibodies (10 μg/mL) that had been separately
incubated at 25°C for seven days, and 37°C for 30 days.
The secondary antibody incubation and detection were
undertaken as described above.Epitope mapping
A total of 171 different peptides with length of 15 amino
acid residues designed to represent different sequences
and regions of PfHRP2 were used in epitope mapping as
previously described [23].Antibody binding affinity determined by Octet
The binding affinity of human mAbs with rPfHRP2 was
determined using anti-human IgG capture (AHC) bio-
sensors in the Octet Red Instrument (Fortebio, USA).
Purified mAbs (20 μg/mL) and ten-fold serially diluted
rPfHRP2 (starting at 50 μg/mL) were prepared in assay
buffer (10 mM phosphate, 150 mM NaCl, 0.02% Tween
20, 0.05% sodium azide, and 1 mg/mL bovine serum albu-
min (BSA), pH7.4). Briefly, a 96-well black microtitre plate
(Perkin Elmer, USA) was prepared and 200 μL of each
sample and buffer were loaded into corresponding wells.
After inserting the hydration plate, both hydrated biosen-
sor assembly and sample plate were equilibrated prior to
the assay starting. The default settings with minor modifi-
cations were used for the assays. The data acquisition at
1 minute/six biosensors, flow rate was at 200 mm/second,
precision was at <10% coefficient of variations (CVs), and
standard curve fit was calibrated at four-parameter logistic
(4-PL) model. The binding rate analysis was performed by
Octet Data Analysis software version 6.1.Results
Biopanning and selection of anti-PfHRP2 scFv clones
A naïve human scFv antibody phage display library was
screened against the immobilized malaria antigen rPfHRP2.
After five rounds of biopanning, the phage pool showed
significant enrichment of binders to rPfHRP2 by polyclonal
phage ELISA analysis (Figure 1). Eighty-four clones were
randomly picked from the fifth round phage pool and
81 showed strong binding in a monoclonal phage
ELISA assay.
Twenty-four positive clones and one negative clone
were chosen for further analysis. PCR-amplified inserts
with an expected size of ~500 bp were achieved in all
clones except one. Of these clones, 13 were found to
have an identical sequence. An additional four clones
also appeared to have this same sequence, although the
sequence data was incomplete. Thus, the population
contained one highly dominant clone. An additional
sequence was represented by two clones: F9 and B6. One
other clone contained an out-of-frame coding region and
corresponded with the ELISA negative clone. Two clones
(D2 and F9) representing the two unique sequences were
selected for further analysis. Sequence analysis of the VH
and VL fragments revealed that both clones belonged
to human immunoglobulin IgHV3 and IgKV1 families,
respectively.
Figure 1 Polyclonal phage ELISA. The diagram shows an increase in ELISA absorbance values in rounds 4 and 5 phage pools against neat, and 1 in
100 diluted rPfHRP2 proteins. Immobilized thioredoxin protein, no phage, and uncoated microtitre plate wells were used as negative controls.
Leow et al. Malaria Journal 2014, 13:277 Page 5 of 12
http://www.malariajournal.com/content/13/1/277Antibody expression
The D2 and F9 scFv fragments were reformatted to
whole mAbs, expressed in CHO cells and purified by
Protein A chromatography [26]. SDS-PAGE analysis of
the purified mAbs showed the whole intact mAb in non-
reducing conditions (~150 kDa), and a 50 kDa heavy
chain and 25 kDa light chain in reducing conditions.
Size exclusion HPLC showed no significant aggregation
or degradation (Figure 2).Figure 2 Analysis of purified recombinant mAbs D2 and F9 on 4-12%
Lane 1: SeeBlue Plus2 Pre-Stained Standard (Invitrogen); Lanes 2 and 3: non-re
reduced mAb D2; Lanes 8 and 9: reduced mAb F9, at neat, and 1 in 10 dilutio
recombinant mAbs D2 and F9 at 280 nm are shown in panels B and C, respeCharacterization of antibody
ELISA was employed to define the titre (endpoint di-
lution) of each mAb against 100 μg/ml of rPfHRP2
(Figure 3). When the cut-off absorbance is set at 0.5, mAb
D2 had the highest end-titre sensitivity at 0.06 ng/mL,
followed by mAb C1-13 at 0.1 ng/mL and mAb F9 at
0.15 ng/mL. No reactions were observed for these mAbs in
ELISA assays and Western blot when rPfHRP2 was
replaced by 1% BSA.SDS-PAGE. The gel was stained with Coomassie Blue R250 (A).
duced mAb D2; Lanes 4 and 5: non-reduced mAb F9; Lanes 6 and 7:
ns. Analytical size exclusion chromatography of protein-A purified
ctively.
Figure 3 Titration of mAbs D2, F9, and C1-13 against 0.1 μg
rPfHRP2 protein. The antibodies were prepared in two-fold serial
dilution, from 20 ng/mL in ELISA assay. 1% BSA protein was used as
a negative control. The dotted line represents cut-off OD absorbance
at 0.5.
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native malaria proteins was evaluated by Western blot
analysis (Figure 4). Both mAbs D2 and F9 reacted to
rPfHRP2, showing a single band at 82 kDa, the correct
size for the thioredoxin-fused protein. For detection of
native parasite proteins from blood stage infection, P.
falciparum-infected red blood cells were tested in West-
ern blot. The results show that all mAbs were capable of
recognizing native PfHRP2 protein at ~50 kDa, with
such band was not detected from uninfected RBC pro-
tein lane. No cross-reactivity with the other two malaria
biomarkers, namely P. falciparum lactate dehydrogenase
(PfLDH) and Plasmodium vivax aldolase (PvAldolase)
was observed on Western blot (Additional file 1) or ELISA
(Additional file 2).
The sensitivity of detecting rPfHRP2 protein by mAbs
was investigated by ELISA and dot blot analysis (Figure 5).
The ELISA data indicated a difference in sensitivity be-
tween three mAbs when comparing the detection limit
against serial diluted rPfHRP2. While 5 μg/mL of mAbs
applied, mAb C1-13 had the highest sensitivity, with an
OD value of 1, the detection achieved 5 ng/mL of
rPfHRP2, followed by mAbs D2 and F9 at 10 ng/mL and
100 ng/mL of rPfHRP2, respectively (Figure 5A). However,
sensitivity fell when less concentrated antibodies were ap-
plied (1 μg/mL) (Figure 5B). These results were consistent
with results of the semi-quantitative studies carried out by
dot blot. Compared to the commercial antibody C1-13,
the sensitivity of both antibodies D2 and F9 was lower.
Detection limits were ten times (D2) and 100 times (F9)
lower than for C1-13.
To determine the accuracy and linearity of rPfHRP2
detection, mAbs of D2 and F9 were each designed as
capture or detection antibodies in sandwich ELISA, in
combination with mAb C1-13. The mean reactivity for
duplicate measures of serially diluted rPfHRP2 proteinfrom 1 μg/mL to 0.01 fg/mL detected by mAbs D2 and
F9 are represented in Figure 6. From the results, both
antibodies D2 and F9 showed binding to rPfHRP2 pro-
tein in heterologous configurations with mAb C1-13.
However, the sensitivity of heterologous antibodies var-
ied despite the use of the same mAbs D2 or F9 as either
capture or detection antibodies. When using an OD cut-
off value of 0.25, the detection limit for D2-Cap/C1-
13-Detection was at 50 pg/mL, whereas C1-13-Cap/
D2-Detection was at 1 pg/mL (Figure 6A). The configur-
ation of mAbs F9 and C1-13 influenced different sensitiv-
ity. The lowest detection limit for F9-Cap/C1-13-Detection
was 5 ng/mL, and C1-13-Cap/F9-Detection was ~0.5 ng/
mL at the OD cut-off value of 0.25 (Figure 6B). Overall,
the configuration of C1-13-Cap/D2-Detection was the
most sensitive for detection of rPfHRP2 protein by ELISA.
Neither heterologous mAbs D2 nor F9 reacted to 1%
BSA protein.
Heat lability of antibodies
The melting point value of mAbs was determined using
DSC analysis (Additional file 3). Two melting point
peaks (Tm) were detected for the mAbs, namely 72°C
and 82°C for mAb D2, and 73°C and 80°C for mAb F9.
Only one melting point of 72°C was observed for the
control antibody C1-13. The precipitation of mAbs D2
and F9 at high temperatures was indicated by a sharp
peak decline and negative Cp values. This phenomenon
was not observed with mAb C1-13, where the Cp values
returning to baseline following Tm peak.
After incubation at different temperatures for different
durations, the heat stability of two recombinant mAbs
were determined by reacting to two-fold serially diluted
rPfHRP2 proteins immobilized on nitrocellulose mem-
brane using dot blot (Additional file 4). mAb C1-13 had
previously been shown to retain its reactivity after incu-
bating at 37°C for 90 days [23]. After incubation at 25°C
for seven days, the binding ability of mAbs D2, F9 and
C1-13 was still maintained (Additional file 4A). The heat
stability of mAbs was different; mAb D2 retained its
binding sensitivity at 37°C compared to 25°C, whereas
loss of sensitivity at 37°C was observed in mAbs C1-13
and F9 (Additional file 4B).
Epitope mapping
In initial epitope mapping, both mAbs D2 and F9 gave
positive reactions to a range of different peptides. mAb
D2 recognized the predominant motif AHHAADAHHA
as its major epitope with possible substitutions of serine
in the fifth amino acid, a similar result to the major epi-
tope recognized by mAb C1-13 [23]. In contrast, the
major epitope recognized by mAb F9 was one amino
acid shorter, lacking an alanine at the end, resulting in
AHHAADAHH.
Figure 4 Western blot analysis for the binding specificity of mAbs against recombinant and native PfHRP2 proteins. A: Separation of
recombinant PfHRP2 and 1% BSA proteins in 10% reduced SDS-PAGE, and stained with Coomassie Blue; B: Hybridization of corresponding recombinant
mAbs D2, F9, and C1-13 to rPfHRP2 (1 μg/mL) and 1% BSA in Western blot. C: Separation of native malaria parasite protein and uninfected RBC by10%
SDS-PAGE, stained with Coomassie Blue. D: hybridization of corresponding recombinant mAbs D2, F9, and C1-13 to malaria native protein (1 μg/mL)
and uninfected RBC protein (1 μg/mL)in Western blot. Lane 1: recombinant HRP2 protein; Lane 2: negative control 1% BSA. Lane 3: P. falciparum-
infected RBC protein; Lane 4: negative control uninfected RBC protein. Molecular weights are shown at the left corner of the diagram.
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A kinetic study was performed to determine the binding
affinity of mAbs to serially diluted rPfHRP2 proteins
from 610–0.0061 nM (Additional file 5). Of the three
mAbs, the highest association constant (ka) value was
displayed by F9 at 1.80 × 106 Ms−1 (Additional file 5B),
whereas D2 was at 8.50 × 105 Ms−1 (Additional file 5A).
In comparison, C1-13, previously measured by Biacore
(Lee et al. unpublished) has an association value of
3.60 × 105 Ms−1 (Lee et al. unpublished). The dissoci-
ation constant (kd) value of F9 was however the lowest
value at 7.66 × 10−5 s−1 compared to D2 (2.59 × 10−4 s−1)
and C1-13 (3.72 × 10−5 s−1).
To understand the binding affinity value, the KD
was calculated by kd/ka. This showed that mAb F9
had the strongest binding affinity to rPfHRP2 protein,
with a KD value of 4.27 × 10
−11 M (Table 1), followed bycontrol mAb C1-13 at 1.03 × 10−10 M and mAb D2 at
3.05 × 10−10 M.
Discussion
Since the introduction of lateral flow immunochromato-
graphic assays for detection of malaria about 20 years
ago [29,30], RDTs have played an increasing role in
improving the quality of case management for malaria
and assist the reduction of unnecessary anti-malarial
drug usage [31,32]. The specificity, sensitivity, affinity,
and heat stability of antibodies are important determi-
nants of the quality and reliability of a RDT.
Current malaria RDTs are developed in formats such as
dipstick, strip, card, pad, well, or cassette [33]. Three types
of antibodies, including signal, capture and control anti-
bodies are generally incorporated in the device to render in-
dication of a complex antibody-antigen interaction [10,33].
Figure 5 Sensitivity of mAbs D2, F9 and C1-13 against rPfHRP2. The binding efficacy of mAbs against serially diluted recombinant PfHRP2 is
determined by ELISA (Left panel) and dot blot (Right panel). A: 5 μg/mL of mAbs; B: 1 μg/mL of mAbs. Dot line represents cut-off OD absorbance at 1.0.
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current commercial available RDTs [34]. The degradation
of antibody performance with long exposure to high tem-
perature has led to a decrease in operational performance
[35]. To address this problem, a selection of quality mAbs
with high affinity, specificity and heat stability to tar-
get antigen is important to improve malaria diagnostic in
tropical regions.
The aim of this study was to generate new mAbs and
assess their binding capability against malaria PfHRP2
antigen. The Sheets naive human scFv phage display
library has been shown to contain binders to a wide
range of different antigens, with affinities achieved in
subnanomolar range [24]. This provided a good rationale
for using this library to isolate novel scFv fragmentstargeting parasite biomarkers. Following five rounds of
biopanning of the Sheets library, two unique scFv clones
with specificity to rPfHRP2 were isolated. These clones
were reformatted to whole IgG1 to allow comparison
with a commercially available mouse antibody against
PfHRP2.
Most antibodies deployed currently in commercial
malaria RDT devices were produced in the early 1990s.
Due to commercial consideration, details such as mAbs
isotype, subclasses, epitopes targeted, and laboratory of
origin are either rarely published or incompletely docu-
mented by manufacturers [22]. Herein, the performance
of the two newly isolated human mAbs produced in
this study was compared with commercially available
mouse mAb C1-13, which was shown to have the highest
Figure 6 Binding reactivity of mAbs D2 and F9 and mAb C1-13
to rPfHRP2 protein. mAbs D2 (A) and F9 (B) were used as capture
antibody (Cap) or detection antibody (Detection) in combination
with mAb C1-13 in sandwich ELISA. The dotted line represents
cut-off OD absorbance at 0.25.
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IgGs targeting PfHRP2 [23].
Both mAbs D2 and F9 exhibited strong binding speci-
ficity and sensitivity against both recombinant and native
PfHRP2, as shown by ELISA and Western blot (Figures 3
and 4). Like C1-13, both reformatted mAbs recognized
rPfHRP2 as a single band on Western blot, suggesting
that the specificity of mAbs D2 and F9 was not affected
by reformatting. In extracts from infected red blood
cells, all mAbs recognized a major band of 50 kDa, the
size of native PfHRP2. The presence of multiple bands
on Western blot is not uncommon when anti-PfHRP2Table 1 Kinetics determination of mAbs D2 and F9
mAb ka (1/Ms) kd (1/s) KD (M)
D2 8.50 × 105 2.59 × 10−4 3.05 × 10−10
F9 1.80 × 106 7.66 × 10−5 4.27 × 10−11
C1-13 3.60 × 105 3.72 × 10−5 1.03 × 10−10
Association (ka), dissociation rates (kd), and equilibrium constants (KD) of mAbs
D2, F9, and C1-13 against rPfHRP2. The analysis for mAbs D2 and F9 were
undertaken using the Octet Red platform, whereas mAb C1-13 was determined
by BIAcore.mAbs are used against native parasite proteins, because
P. falciparum has several histidine-rich proteins [36].
One of these is PfHRP3, a protein highly similar to
PfHRP2 in amino acid sequence with a molecular weight
of approximately 35–37 kDa [37]. Antibodies against
PfHRP2, such as mAb C1-13, have been reported to
bind to PfHRP3 [23]. However, only two bands (50 kDa
and 37 kDa) were recognized by mAb D2, while one
band (50 kDa) by mAb F9, suggesting these mAbs may
have higher specificity than C1-13 [38,39].
When D2 and F9 antibodies were tested either as
capture antibody or detection antibody by partnering
with mAb C1-13 (Figure 6), both antibodies showed
no significant loss of sensitivity of binding in the sandwich
format. The detection sensitivity was best when mAb
C1-13 was used as capture antibody although different
secondary antibodies used for detection may contribute to
the detection sensitivity. As an extensive number of re-
peated epitopes exist in PfHRP2 [6], epitope numbers are
not likely contributing to the difference in binding of
mAbs [40]. The difference may result from better binding
affinity of mAb C1-13 to the double HHA (amino acid
residues) sequence on antigenic site of PfHRP2 epitopes.
However, mAb C1-13 was shown to possess lower affinity
than mAb F9. Therefore the causes contributing the bind-
ing behaviour of these mAbs remain unclear.
The Octet Red® system was chosen to examine, in real
time, the rate of association (binding) and dissociation
(unbinding) of mAbs D2 and F9 to rPfHRP2 protein.
The mAb F9 showed the highest binding affinity (KD of
40 pM), although it had a weaker sensitivity in the ELISA
screening (Figure 5). This was followed by mAbs C1-13
(0.1 nM) and D2 (0.3 nM). These are very strong affinities,
despite being isolated from a naive library, which may in
part be explained by the nature of the epitope. The opti-
mal epitope recognized by mAb D2 was identical to that
recognized by mAb C1-13, namely AHHAADAHHA.
Despite having the same epitope, mAbs C1-13 and D2 are
able to simultaneously bind to PfHRP2 in a sandwich
ELISA, since this epitope is present in many repeats along
the PfHRP2 sequence as evidenced by the large number of
analysed peptides from PfHRP2 that were able to bind
these mAbs (41-60%) [23]. The repetitive nature of this
epitope contributes to the very slow dissociation rates of
these mAbs, as the antigen is providing high avidity, and
consequently an apparent strong affinity. These factors are
contributing to the poor fit of a kinetic binding model,
which assumes a 1:1 interaction, shown in Additional
file 5, so the kinetic values are an estimate only.
This strong apparent affinity is ideal for RDTs as mAbs
that have a faster rate of association and slower rate of
disassociation (a low kd value) would be considered to
give a greater binding ability to target biomarker. Thus,
the kinetic properties of mAbs D2 and F9 make them
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comparable to the commercially available mAb C1-13,
which has been shown to be superior to PfHRP2-specific
IgM isotype antibodies [23].
Another aspect that important for reagents used in
RDTs in the tropical and subtropical world is their ability
to withstand high ambient storage temperatures. The
experiment identified 72°C as the melting point for mouse
mAb C1-13, 82°C and 80°C for D2 and F9, respectively
(Additional file 3). When temperature gradually increased
(>82°C), protein precipitation was not observed in control
mAb C1-13 but was for both mAbs D2 and F9. Peaks in
the readout trace may correspond to different parts of the
mAb (eg the Fab region and Fc region) unfolding. Accord-
ing to literature, the CH2 domain of an antibody tends to
unfold earlier, followed by the Fab and the CH3 domains.
The thermal transition of the Fab domain commonly oc-
curs between the CH2 and CH3 domains or overlapping
with either one of this domain in a monoclonal antibody
[41]. Furthermore, major difference in the amino acid
composition between mouse and human immunoglobu-
lins is another likely factor that resulted in these mAbs
having different thermal stability [42-44]. The non-
precipitation of mAb C1-13 indicated by Cp values
returning to baseline shows this mAb possesses reversibil-
ity, which might not be found in the human mAbs D2 and
F9. Due to lack of information about this commercial
mAb, the complete amino acid composition and the pro-
duction method were not available. However, this varying
melting temperature may be influenced by thermo-
dynamic interactions within the antibody domains, and
conformational changes in human and mouse mAbs that
correspond to the aggregation and precipitation of the un-
folded protein [45,46].
In terms of stability, the unfolding of the human and
mouse IgG1 at pH 5.5 generally present two transitions,
with melting temperature around 70°C and 82°C. The
unfolding of Fab fragment normally occurs at lower tem-
peratures 70°C, whereas 82°C for Fc fragment [41].
Based on this finding, it may be speculated that the first
and second unfolding events in the human mAbs are
analogous with mouse mAbs. Therefore, human mAbs
D2 and F9 may be expected to share a similar stability
with mouse mAb C1-13 although only one peak was
observed in mouse antibody. In addition to different
melting profiles, the sequence of the variable domains
is another factor potentially affecting the stability of
the Fab fragment from either human or mouse [47].
Overall, the observation of melting point for mouse
mAb C1-13, and human mAbs D2 and F9 suggested
the mAbs produced in this study are more heat stable
(by DSC analysis), but in practical terms when comparing
stability at 25°C and 37°C all three mAbs exhibit similar
stability.In summary, phage display is a promising tool that al-
lows the selection of new binders by undergoing iterative
rounds of biopanning. In this study, two scFv clones iso-
lated from human scFv naïve library were shown to have
high affinity and specificity against PfHRP2 proteins.
The binding efficacy of these recombinant mAbs was
demonstrated to be comparable to commercial mAb C1-
13. However, this system has some disadvantages, in-
cluding duration of expression and expense of the
eukaryotic expression system that may inhibit the use of
the current system for manufacture of mAbs for malaria
RDTs. Therefore, alternative expression method may be
preferable. In addition, false positive results that oc-
curred between native human RBC with anti-human
antibodies, suggesting human Fc region might not be an
ideal detection region for mAb recognition. Thus, tag-
ging of the mAb, for example by biotinylation, may po-
tentially reduce the cross-reactivity problem.
Conclusions
Five rounds of biopanning resulted in selection of two
high affinity clones from a naïve library. Recombinant
mAbs D2 and F9, expressed by mammalian cells, are
high quality mAbs which exhibited excellent binding
capability to rPfHRP2. These antibodies were also dem-
onstrated to have specificity and sensitivity comparable
to commercial mAb C1-13 but with potentially better
thermostability. Therefore, the mAbs produced in this
study may be suitable for evaluation by undergoing field
test in different malaria endemic regions in a prototype
test kit.
Additional files
Additional file 1: Cross-reactivity determination of recombinant
mAbs against three different malaria biomarkers in Western blot
analysis. Cross-reactivity determination of recombinant mAbs against
three different malaria biomarkers in Western blot analysis. Lane 1:
rPfHRP2; Lane 2: rPfLDH; Lane 3: rPvAldolase. The molecular weight and
purity of each malaria biomarker is shown in panel A. The reactivity of
mAbs D2, F9, and C1-13 are represented by panel B, C, and D,
respectively.
Additional file 2: Cross-reactivity determination of recombinant
mAbs against three different malaria biomarkers in ELISA analysis.
The reactivity of mAbs D2, F9, and C1-13 are represented by panel A, B,
and C, respectively.
Additional file 3: The melting point for three mAbs in PBS pH 7.2
buffer by DSC analysis. Calculated Tms for 1 mg/mL mAb C1-13
(purple) was 72°C; 1 mg/mL mAb D2 (green) had 2 peaks at Tms of 72°C
and 82°C; and 0.5 mg/mL of mAb F9 (magenta) had two peaks at Tms
of 73°C and 80°C. mAbs D2 and F9 precipitated at high temperatures
indicated by sharp peak decline and negative Cp values. Control mAb
C1-13 did not precipitate indicated by Cp values returning to baseline
following Tm peak.
Additional file 4: Determination of heat stability at different
temperatures and durations. Dot blot was used to determine the
heat stability of mAbs on a nitrocellulose membrane immobilized with
two-fold serially diluted rPfHRP2 (starting at 1 μg/mL). The tested mAbs
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http://www.malariajournal.com/content/13/1/277were incubated at 25°C for 7 days (A) and, at 37°C for 30 days (B) prior to
hybridize to rPfHRP2 proteins.
Additional file 5: Determination of mAbs affinity by Octet
sensogram. Sensogram showing two mAbs binding to serially diluted
rPfHRP2 proteins from 600 nM to 0.0061 nM. mAb D2 is represented in
panel A. mAb F9 is represented in panel B. Coloured lines represent the
binding interactions of mAb to different concentration of rPfHRP2. Red
lines represent the statistical fitting of curves.
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